Compare Live Nation Entertainment, Inc. (LYV) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs BIO-TECHNE Corp — how do they compare? Live Nation Entertainment, Inc. trades at $170.86 (market cap $39.92B), while BIO-TECHNE Corp trades at $72.44 (market cap $11.36B). The key difference: Live Nation Entertainment, Inc. is far larger — about 3.5× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Live Nation Entertainment, Inc. for 72 Days and BIO-TECHNE Corp for 64 Days on average.
| LYV | TECH | |
|---|---|---|
Market Cap | $39.92B | $11.36B |
Volume | 1,982,609 | 5,390,331 |
Sector | Media | Health |
52-Week High | $188.46 | $72.61 |
52-Week Low | $125.61 | $43.31 |
Typical Hold Time | 72 Days | 64 Days |
Enterprise Value | $42.13B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYV trades at $172.10, up 0.74% today, with a bullish technical signal and strong analyst support. Revenue grew to $25.20B in 2025, though net income margin narrowed to 1.96%. Recent news highlights robust fan demand and strategic partnerships, while the stock faces high valuation multiples and regulatory scrutiny.
Outlook remains positive with a consensus price target of $208.18, but risks include elevated P/E of 117.49, debt levels, and legal uncertainties. Earnings momentum is mixed, with Q2 2026 beating estimates but Q1 and Q4 2025 missing, underscoring execution challenges amid growth.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
